Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

ELDNBullishIndustry Newsnews

High materiality8/10

Eledon advances on positive 12-month PRO data for tegoprubart in kidney transplant

Oct 26, 2026, 7:23 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive Phase 2 PRO data can attract attention from investors expecting long-run adoption or pivotal-trial progression; historical biotech data triggers often lead to short- to mid-term stock moves, though reliance on later-stage data remains high.

AI summary

What happened, with direct paths to the underlying reporting

ELDN announced positive Phase 2 BESTOW patient-reported outcomes for tegoprubart in kidney transplantation, with 12-month improvements versus tacrolimus on MTSOSD-59R and KDQOL-SF scales. The results support a differentiated clinical profile and potential shift in standard of care, pending further studies and regulatory progress.

Tegoprubart improved MTSOSD-59R symptoms at 12 months vs tacrolimus.
KDQOL-SF Symptoms and Problems improved for tegoprubart through 12 months.
Phase 2 BESTOW results show differentiated clinical profile vs standard care.
Data could transform kidney transplant standard of care if validated.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Eledon advances on positive 12-month PRO data for tegoprubart in kidney transplant

Eledon Pharmaceuticals' Lead Asset Fails In Mid-Stage Study, But Pushes Forward With Pivotal Study